智通财经APP讯，兆科眼科-B(06622)公布2024年业绩，收益6932.4万元，同比增长约2.7倍。净亏损约2.37亿元，同比收窄38.32%;每股亏损0.43元。
公告称，收益增长主要源于根据日期为2020年10月2日的产品许可协议收取有关阿达帕林╱盐酸克林霉素复方凝胶的里程碑付款人民币3350万元，令许可收入增加。此外，公司喜见年内的医院覆盖面取得突破，加上成功实行创新的全通路商业化策略及营销计划，令旗下的贝美素噻吗洛尔滴眼液(晶贝莹®)及睿保特等主要眼科药品的销售额增加逾五倍，总收益达人民币3040万元，而2023年则为470万元。于2024年，集团的商业化团队奋力巩固与公私营医院以及眼科机构的关系。
亏损收窄主要源于集团根据一份产品许可协议收取里程碑付款3350万元，以及在医院覆盖面取得突破推动下，眼科药品销售额大幅增长。此外，已届较后期阶段的临床试验(例如NVK002及TAB014的第III期临床试验)圆满完成，令研发开支有所减少，加上提高经营效率减省行政费用，均带动本年度取得的亏损显著减少。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.